Evaluating an early-stage biotech or healthtech startup cannot stop at financial projections and market trends. A company that looks compelling on a spreadsheet still has to prove it has the science, the regulatory strategy, and the leadership to bring a product to market — which is why venture diligence in this sector is, as life sciences equipment leasing firm Excedr puts it, "a deep, multi-step process that goes far beyond a surface-level review."
Introduction: Navigating Early-Stage Biotech Investments
The stakes explain the depth of scrutiny. Excedr's guidance for life sciences investors highlights the defining risk of the asset class: scientific uncertainty. Even with strong research behind it, a drug may fail clinical trials, and a device may never clear regulatory review. Meanwhile, the development clock is long. A Pharmaceutical Research and Manufacturers of America pharmaceutical industry review — drawing on 6,151 successful phase transitions across 2011–2020 — found that a drug that ultimately reached approval took an average of 10.5 years to progress from Phase I through the regulatory stage.
That combination of binary outcomes and decade-long timelines is exactly why a structured checklist matters. Biotech advisory content from Qubit Capital frames diligence not as an exhaustive procedure but as a framework "to help investors identify critical factors that influence decision-making in this complex sector." The three pillars below organize those factors, and the checklist table that follows turns them into a repeatable assessment tool.





